Click here to read the articles and view the interactive digital edition

Pharmaceutical Commerce - August 2025

Despite the ongoing turmoil over tariffs, medicine costs, and FDA policy, US wholesalers are performing well.

Pharma Wholesalers: Looking for Growth

From rethinking launch price logic to implementing rebate-aware modeling and patient-first access programs, this installment explores how disciplined governance and forward-thinking models can safeguard profitability in a volatile market.

Popping the Gross-to-Net Bubble, Part V: Innovative Pricing Models

As pharma drug pricing debates heat up, the 340B program faces mounting challenges from outdated regulations, duplicate discounts, and limited transparency.

340B Litigation and the Path Toward Transparent Drug Discount Programs

. He can be reached at nsaraceno@mjhlifesciences.com.

Videos

In the first part of his Pharma Commerce video interview, Hyung Heon Kim, CEO of MetaVia, describes the US payer ecosystem’s level of preparedness to support broader access and long-term affordability for these therapies.

Coverage Gaps and Challenges Ahead for Obesity Drugs

Articles

Pharma Pulse 7/21/25: Leveraging Real World Evidence to Enhance Safety Monitoring in Obesity Studies; Emrelis and the Evolving Landscape of Antibody Drug Conjugates

In the final part of his Pharma Commerce video interview, Sean O’Hearen, founder and principal consultant at 1st Line Partners, offers communication strategies for staying confident in genuine pharmaceuticals while also remaining vigilant against counterfeit threats.

Balancing Awareness and Assurance

The acquisition merges eBlu’s automation platform with Knipper’s nationwide distribution network, streamlining benefit verification, prior authorization, and patient onboarding while reducing administrative burdens for specialty providers.

Knipper Health Purchases eBlu Solutions to Accelerate Therapy Initiation

Industry stakeholders suggest how pharmaceutical companies can proactively plan for the potential implementation of a Most Favored Nation (MFN) pricing model.

Planning for Market Sustainability Under New Policy Frameworks

In the final part of his Pharma Commerce video interview, Murray Aitken, executive director, IQVIA Institute for Human Data Science, details how he sees the competitive landscape evolving

How Competition, Access, and Reimbursement Will Shape the Next Wave of Innovation

In the fourth part of this roundtable discussion, a panel of subject matter experts dive into data exchange challenges relating to the Drug Supply Chain Security Act.

Peer Exchange: How DSCSA Is Transforming Supply Chain Data Exchange (Episode 4)

The study reveals that resilience varies significantly by race, education, income, and insurance status, highlighting the role of social determinants and systemic inequities in shaping health outcomes.

Racial, Social, and Economic Factors Drive Resilience During COVID-19 Pandemic, Study Finds

In the fourth part of his Pharma Commerce video interview, Sean O’Hearen, founder and principal consultant at 1st Line Partners, describes the prominence of underreporting falsified medicines. 

The Hidden Challenge of Reporting Counterfeit Medicines

Pharma Pulse 7/18/25: How Parexel Supports Cross Functional Trials for Emerging GLP-1 Therapies; Eisai Explores Novel Dual Mechanism Therapy for Advanced Endometrial Carcinoma

Featured Content

Pharmaceutical Commerce - August 2025

Pharma Wholesalers: Looking for Growth

Popping the Gross-to-Net Bubble, Part V: Innovative Pricing Models

340B Litigation and the Path Toward Transparent Drug Discount Programs